Holen Sie sich die Stockscreener-App
51.52
2.59%
1.30
Handel nachbörslich:
52.01
0.49
+0.95%
Schlusskurs vom Vortag:
$50.22
Offen:
$50
24-Stunden-Volumen:
1.35M
Relative Volume:
0.79
Marktkapitalisierung:
$4.98B
Einnahmen:
$4.10M
Nettoeinkommen (Verlust:
$-568.53M
KGV:
-8.2939
EPS:
-6.2118
Netto-Cashflow:
$-401.18M
1W Leistung:
+2.14%
1M Leistung:
-0.60%
6M Leistung:
-9.23%
1J Leistung:
-28.27%
1-Tages-Spanne:
$49.76
$52.37
1-Wochen-Bereich:
$48.91
$54.07
52-Wochen-Spanne:
$44.12
$75.06
Crispr Therapeutics Ag Stock (CRSP) Company Profile
Firmenname
Crispr Therapeutics Ag
Sektor
Branche
Telefon
(617) 315-4600
Adresse
BAARERSTRASSE 14, ZUG
Compare CRSP vs VRTX, MRNA, REGN, ARGX, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CRSP
Crispr Therapeutics Ag
|
51.52 | 4.98B | 4.10M | -568.53M | -401.18M | -6.2118 |
VRTX
Vertex Pharmaceuticals Inc
|
508.75 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.34 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.27 | 53.22B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.08 | 42.32B | 5.76B | 514.49M | 1.10B | 4.4813 |
Crispr Therapeutics Ag Stock (CRSP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-06-11 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2025-09-18 | Eingeleitet | JP Morgan | Overweight |
| 2025-02-14 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2025-02-12 | Hochstufung | TD Cowen | Sell → Hold |
| 2025-02-03 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-08-06 | Bestätigt | Needham | Buy |
| 2024-08-02 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-06-28 | Fortgesetzt | Guggenheim | Neutral |
| 2024-02-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-12-11 | Herabstufung | TD Cowen | Market Perform → Underperform |
| 2023-10-17 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-09-27 | Eingeleitet | Mizuho | Buy |
| 2023-08-17 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-05-30 | Eingeleitet | William Blair | Outperform |
| 2023-04-13 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-03-21 | Eingeleitet | Bernstein | Mkt Perform |
| 2023-03-17 | Eingeleitet | Bryan Garnier | Buy |
| 2023-03-07 | Eingeleitet | Robert W. Baird | Neutral |
| 2022-10-11 | Eingeleitet | Morgan Stanley | Underweight |
| 2022-08-09 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2022-06-23 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-06-17 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-04-28 | Eingeleitet | Credit Suisse | Neutral |
| 2021-12-07 | Eingeleitet | Cowen | Market Perform |
| 2021-10-19 | Eingeleitet | SVB Leerink | Outperform |
| 2021-06-14 | Hochstufung | Citigroup | Sell → Neutral |
| 2021-04-21 | Hochstufung | Jefferies | Hold → Buy |
| 2021-03-04 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2020-12-10 | Bestätigt | Chardan Capital Markets | Buy |
| 2020-12-10 | Herabstufung | Jefferies | Buy → Hold |
| 2020-12-10 | Bestätigt | Needham | Buy |
| 2020-12-07 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-10-23 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2020-10-05 | Eingeleitet | BofA Securities | Buy |
| 2020-07-28 | Bestätigt | Needham | Buy |
| 2020-07-14 | Eingeleitet | SunTrust | Buy |
| 2020-06-15 | Bestätigt | Canaccord Genuity | Buy |
| 2020-03-05 | Eingeleitet | Stifel | Hold |
| 2020-02-03 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-11-19 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2019-11-12 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2019-08-01 | Eingeleitet | Jefferies | Buy |
| 2019-07-26 | Eingeleitet | Canaccord Genuity | Buy |
| 2019-06-10 | Eingeleitet | ROTH Capital | Buy |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2019-03-14 | Eingeleitet | William Blair | Mkt Perform |
| 2019-01-28 | Herabstufung | Goldman | Buy → Neutral |
| 2019-01-22 | Herabstufung | Citigroup | Neutral → Sell |
Alle ansehen
Crispr Therapeutics Ag Aktie (CRSP) Neueste Nachrichten
Matchpoint Therapeutics Expands Leadership Team with Appointment of John O’Malley, M.D., Ph.D., as Chief Medical Officer - GlobeNewswire Inc.
Moderna vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
CRISPR Therapeutics AG (CRSP) Dips More Than Broader Market: What You Should Know - Zacks Investment Research
Roche Reports Positive Phase III Data on Eye Drug, FDA Accepts BLA - Zacks Investment Research
Here is What to Know Beyond Why CRISPR Therapeutics AG (CRSP) is a Trending Stock - Yahoo Finance
Here is What to Know Beyond Why CRISPR Therapeutics AG (CRSP) is a Trending Stock - Zacks Investment Research
Analysts Conflicted on These Healthcare Names: Quantum-Si (QSI), Crispr Therapeutics AG (CRSP) and Ultragenyx Pharmaceutical (RARE) - The Globe and Mail
CRISPR Therapeutics AG (1CG.F) stock price, news, quote and history - Yahoo Finance UK
Cathie Wood’s ARK sells DraftKings stock and buys CRISPR Therapeutics - Investing.com
CRISPR Therapeutics (NASDAQ:CRSP) Shares Climb 5.7%What's Next? - MarketBeat
Citi Sees 60% Upside in CRISPR Therapeutics. Here's What Has to Go Right. - The Motley Fool
BofA Adjusts Price Target on CRISPR Therapeutics to $81 From $82, Keeps Buy Rating - marketscreener.com
BofA Adjusts Price Target on CRISPR Therapeutics to $81 From $82, Keeps Buy Rating - Yahoo Finance
CRISPR Therapeutics AG (NASDAQ:CRSP) Stock Rated "Moderate Buy" by Sell-Side Brokerages - MarketBeat
Counsel exercises options and sells 1,990 CRISPR Therapeutics (CRSP) shares under a trading plan. - Stock Titan
AbbVie's Temab-A Gets Two FDA Breakthrough Therapy Tags in Cancer - Zacks Investment Research
Ultragenyx to Sell Rare Pediatric Disease PRV for $210M to Boost Cash - Zacks Investment Research
CRISPR Therapeutics to Present Late-Breaking Data at the American Heart Association (AHA) Scientific Sessions 2026 - GlobeNewswire
Trial data on a gene-editing treatment for very high triglycerides will be presented at a heart meeting. - Stock Titan
Form 144 CRISPR THERAPEUTICS AG For: 7 October By Investing.com - Investing.com Nigeria
CRISPR Therapeutics AG (CRSP) Stock Slides as Market Rises: Facts to Know Before You Trade - Zacks Investment Research
CRISPR Therapeutics AG (CRSP) Stock Slides as Market Rises: Facts to Know Before You Trade - Yahoo Finance
Officer James Kasinger proposes selling 1,990 shares of CRISPR Therapeutics (CRSP). - Stock Titan
CRISPR Therapeutics (NASDAQ:CRSP) Shares Gap UpHere's What Happened - MarketBeat
Wall Street Bulls Look Optimistic About CRISPR Therapeutics (CRSP): Should You Buy? - Yahoo! Finance Canada
Wall Street Bulls Look Optimistic About CRISPR Therapeutics (CRSP): Should You Buy? - Yahoo Finance
CRISPR Therapeutics to Present Phase 1 Data on Zugo-cel in Refractory Systemic Sclerosis at ACR Convergence 2026 - Quiver Quantitative
An experimental scleroderma treatment uses immune cells with changed genes. Early data will be presented Nov. 8. - stocktitan.net
CRISPR Therapeutics to Present Clinical Data on Zugocabtagene Geleucel (Zugo-cel) in Autoimmune Disease at the American College of Rheumatology (ACR) Convergence 2026 - GlobeNewswire
CRISPR Therapeutics AG (CRSP) Stock forecasts - sg.finance.yahoo.com
Total common shares outstanding of CRISPR Therapeutics AG – HAN:1CG - TradingView
Pretax income of CRISPR Therapeutics AG – HAN:1CG - TradingView
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know - Zacks Investment Research
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know - finance.yahoo.com
CRISPR Therapeutics Has 2 Key Catalysts Coming by the End of 2026. Is the Market Underestimating Them? - The Motley Fool
CRISPR Therapeutics Has 2 Key Catalysts Coming by the End of 2026. Is the Market Underestimating Them? - finance.yahoo.com
CRISPR Therapeutics stock price target reaffirmed at $80 by Citizens - Investing.com
One CRISPR treatment cut “bad” cholesterol in half for a full year - sciencedaily.com
CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: Here's Why - Yahoo Finance
CRISPR Therapeutics stock analysis: pipeline catalysts vs. financial reality - Investing.com
CRISPR Therapeutics' General Counsel James R. Kasinger Sells 10,400 Shares Following Option Exercise - Kalkine Media
Form 4 CRISPR Therapeutics AG For: 24 September By Investing.com - Investing.com Nigeria
Form 4 CRISPR Therapeutics AG For: 24 September By Investing.com - Investing.com South Africa
Form 4 CRISPR Therapeutics AG For: 24 September By Investing.com - Investing.com Canada
CRISPR Therapeutics (NASDAQ:CRSP) General Counsel James Kasinger Sells 10,400 Shares of Company Stock - MarketBeat
CRISPR Therapeutics (CRSP) counsel exercised options and sold 10,400 shares under a trading plan. - Stock Titan
CRISPR Therapeutics' Casgevy sales jump 78% in Q2, boosting long-term buy case despite AI gene editing risks - Pluang
Crispr Therapeutics: Why AI Giant Anthropic's Discovery Has Rocked Gene Editing (CRSP) - Seeking Alpha
CRISPR Therapeutics vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
CRISPR Therapeutics (CRSP) Shares Dip Amid Anthropic AI Enzyme D - GuruFocus
Finanzdaten der Crispr Therapeutics Ag-Aktie (CRSP)
Umsatz
Nettogewinn
Free Cashflow
ENV
Crispr Therapeutics Ag-Aktie (CRSP) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| SIMEON GEORGE | Director |
Oct 14 '26 |
Proposed Sale |
49.63 |
14,514 |
720,373 |
0 |
| Kulkarni Samarth | Chief Executive Officer |
Oct 14 '26 |
Sale |
49.26 |
4,098 |
201,867 |
259,736 |
| KASINGER JAMES R. | General Counsel and Secretary |
Oct 06 '26 |
Sale |
60.04 |
1,990 |
119,481 |
94,784 |
| KASINGER JAMES R. | General Counsel and Secretary |
Oct 06 '26 |
Option Exercise |
13.62 |
1,990 |
27,104 |
96,774 |
| JAMES KASINGER | Officer |
Oct 06 '26 |
Proposed Sale |
60.04 |
1,990 |
119,481 |
0 |
| KASINGER JAMES R. | General Counsel and Secretary |
Sep 22 '26 |
Sale |
60.24 |
10,400 |
626,460 |
94,784 |
| KASINGER JAMES R. | General Counsel and Secretary |
Sep 22 '26 |
Option Exercise |
13.62 |
10,400 |
141,648 |
105,184 |
| JAMES KASINGER | Officer |
Sep 22 '26 |
Proposed Sale |
60.24 |
10,400 |
626,460 |
0 |
| Behbahani Ali | Director |
Sep 17 '26 |
Sale |
57.09 |
13,679 |
780,935 |
16,637 |
| ALI BEHBAHANI | Director |
Sep 17 '26 |
Proposed Sale |
57.09 |
13,679 |
780,935 |
0 |
0.90%
2.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):